semaglutide hepatic impairment child pugh 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial semaglutide hepatic impairment child-pugh Child-Pugh

However, two considerations matter when stopping: 1

this effect was sustained for 24 weeks

Peak action of NPH Meal Regular Regular NPH NPH Reduce NPH insulin Split-mixed insulin Advantages Less hypoglycaemia, with fine tuning More physiologic Adjustable meal pattern Disadvantages More patient education required Cumbersome mixing Pen device not feasible if two injections are planned for

CMRs diagnostic accuracy improves when performed closer to the event and also serves as a prognostic tool for long-term cardiovascular outcomes

You should disclose the brand name (Mounjaro or Zepbound), current dosage, indication for use (diabetes or weight management), duration of therapy, any recent dose changes, and current side effects

Could GLP-1 receptor agonists transform the treatment of Alcohol Use Disorder